A B S T R A C T An in vitro method was used to detect adherence of 51Cr-labeled platelets to monolayers of cultured human endothelial, fibroblast, and smooth muscle cells. Washed platelets did not adhere to untreated or aspirin-treated endothelial monolayers in the absence of thrombin. In contrast, thrombin-induced platelet aggregates adhered to all of the monolayers but adherence to endothelium was significantly less than to the other cells. Additional evidence for adherence of platelets to the endothelium was provided by scanning and transmission electron microscopy. Thrombin-induced platelet adherence to endothelium was inhibited by hirudin. Platelet adherence induced by thrombin was enhanced significantly by treatment of the endothelial monolayer with 1-2 mM aspirin. This increase in adherence was seen even when aspirin-treated platelets were used; adherence values approached those seen with fibroblasts and smooth muscle cells. An aspirin concentration of 0.1 mM was sufficient to block thrombin-induced malonaldehyde production in platelets but it did not interfere with the inhibitory effect of the endothelium against platelet adherence. The effect of aspirin on the endothelium was temporary and inhibitory activity of the endothelium was restored 1 h after aspirin had been removed from the incubation system. The ability of thrombin to cause adherence of platelets to undamaged endothelium, and the potential for aspirin to enhance this adherence have implications for mechanisms which operate in platelet interaction with the blood vessel wall.
INTRODUCTION
The interaction of platelets with the vessel wall plays an important role in hemostasis and in the development of thrombotic lesions. The capacity of platelets to adhere to the subendothelial structures after denudation of the endothelium, has been adequately demonstrated (1) (2) (3) (4) (5) (6) and is generally accepted. Less understood is the ability of platelets to adhere to the intact endothelium either as a consequence of altered flow characteristics, endothelial injury without detachment, or the effect of procoagulants (7) (8) (9) (10) .
To study the effect of procoagulants on platelet-vessel wall interactions, a modification of the in vitro model system reported by Winkelhake and Nicolson (11) was employed to delineate the adherence capabilities of the various cells which compose the vessel wall. In the present study endothelial cells from the umbilical vein, and smooth muscle cells and fibroblasts from the umbilical artery were used. This report details the adhesive properties of 51Cr-labeled platelets to these cell monolayers as a consequence of incubation of the platelets with thrombin. The results indicate that platelet aggregates are much more adherent to smooth muscle cells or fibroblasts, the subendothelial cellular components, than they are to the endothelium. Ofparticular interest was the demonstration that thrombin had the potential to cause platelets to adhere to the undamaged endothelium and that this effect was enhanced by treatment of the endothelium with aspirin.
METHODS
Reagents. Powdered medium 199 (with Earle's salts, with L-glutamine, without NaHCO3), Hanks' balanced salt solution (lOx), Eagle's basal medium vitamin solution (100x), Eagle's basal medium amino acids solution (IOOx), and calcium and magnesium-free Dulbecco's phosphate-buffered saline (PBS)' Abbreviations used in this paper: ACD, acid citrate dextrose anticoagulant; ASA, acetylsalicylic acid or aspirin; FCS, were purchased from Grand Island Biological Co., Grand Island, N. Y. Human thrombin prepared by activation of prothrombin with citrate, Trizma base (Tris), Hepes buffer, hirudin (Grade II), and EDTA were obtained from the Sigma Chemical Co., St. Louis, Mo. Sodium chromate 51Cr, was purchased from E. R. Squibb & Sons, Princeton, N. J. Sodium heparin was purchased from Abbott Diagnostics, North Chicago, Ill. Topical bovine thrombin was obtained from Parke, Davis & Co., Detroit, Mich. Highly purified human thrombin, prepared by activation of prothrombin with Taipan snake venom (12) , was kindly provided by Dr (14) (15) (16) . Empty dish controls consisted of 35 x 10-mm Petri dishes which were incubated with MM-199 with 20% FCS and handled exactly as dishes containing cells.
Preparation of labeled, washed platelet suspensions. The isolation and washing of platelets was a modification of the procedure described by Mustard et al. (13) . Venous blood was taken from normal, nonfasting human donors who had not taken aspirin or other antiplatelet drugs for 10 days and, in the case of women, were not using oral contraceptives. Five parts blood was mixed with one part of the acid citrate dextrose (ACD) anticoagulant of Aster and Jandl (17) . 100 ml blood, mixed with 20 ml ACD, was centrifuged in 40 ml siliconized centrifuge tubes at 325 g for 15 min and the resulting platelet-rich plasma was separated. The platelet-rich plasma was centrifuged at 1,000 g for 15 min and the platelet pellet was resuspended in 10 ml ofthe above-defined Tyrode's solution and 0.4 ml ACD. If aspirin-treated platelets were required, the Tyrode's solution contained aspirin and a platelet number not exceeding 1.5 x 106 platelets/ml. After the addition of 250 U heparin and 100 ,LCi Na25ICrO4 (0.5-1.0 ml) the platelet suspension was incubated at 37°C for 20 min. The pellet resulting from centrifugation at 650 g for 10 min was resuspended in 10 ml Tyrode's solution and 0.4 ml ACD, and then recentrifuged at 650 g. Platelets were resuspended in a second washing solution which consisted of 10 ml Tyrode's solution and 0.2 ml ACD. A final centrifugation at 650 g yielded a pellet which was resuspended in 9 ml Tyrode's solution. 0.5 ml of this labeled platelet suspension contained -15,000-20,000 cpm of5ICr radioactivity and 5-7 x 106 platelets. As determined by phase microscopic examination, platelet suspensions were free of aggregates. Suspensions were stored at 37°C if not immediately used but in all cases were incubated with the cell monolayers not later than 4 h after the blood was drawn. Platelets did not aggregate spontaneously during this period.
Aggregation studies. Control studies with a Payton aggregation module (Payton Associates, Buffalo, N. Y.) were performed at the same time that suspensions were incubated with the thrombin treated monolayer. Thrombin, at a final concentration of 0.06 U/ml, was used to aggregate both untreated or aspirin-treated platelets suspended in Tyrode's solution with IM.
Malonaldehyde (MDA) assay. Aliquots of the initial ACD platelet-rich plasma and the final platelet wash suspension were immediately assayed. Platelets were resuspended in 1.5 ml of 0.5 U/ml bovine thrombin in PBS or 1.5 ml PBS (control). MDA was determined by the method of Stuart et al. (18) , with the modification that 1.5 ml thiobarbituric acid solution was employed.
After MDA assay the tube containing platelets and MDA reagents was centrifuged at 1,100 g for 15 min. The resulting platelet pellet was washed with 5 ml PBS, recentrifuged, and solubilized with 1.0 N NaOH. Protein was determined by the procedure of Lowry et al. (19) and was converted to platelet count by the factor 1 x 109 platelets/1.7 mg protein (20) . MDA was normalized to nanomoles/109 platelets. Thrombin stimulated MDA equals MDA (thrombin platelets) minus MDA (control platelets).
Adherence of preformed platelet aggregates to cell monolayers. 1 ml IM and 0.5 ml 51Cr-platelets in Tyrode's solution were stirred in the Payton aggregation module at 1,000 rpm and 37°C for 3 min. 25 ,u IM (control) or 25 ,ul 4 U/ml bovine thrombin in IM was added to the platelet suspension and aggregation was monitored on the strip chart recorder. As soon as maximal aggregation was indicated the platelets were poured onto the cell monolayer, which had been washed previously with two 1.5-ml portions of MHBSS. In additional studies the excess thrombin was first neutralized by stirring the aggregated platelets in the cuvette with 25 ,l 4 U/ml hirudin for 1 min before transfer to the monolayer. The 35 x 10-mm Petri dish, containing the cell monolayer and platelet suspension, was placed in a 37°C metabolic incubator on a rocker platform with a 300 tilt (Bellco Glass Inc., Vineland, N. J.) and rocked continuously at a rate of 10 up-and-down cycles per min. After 30 min incubation the suspension containing unattached platelets was transferred to a plastic centrifuge tube. After the addition of 1.5 ml MHBSS solution the dish was returned to the rocker for 5 min. This 1.5-ml MHBSS solution and an additional 1-ml MHBSS wash (no rocking) were placed in the centrifuge tube containing the unattached platelets. After centrifugation at 1,000 g for 10 min, 51Cr radioactivity in the tube was immediately counted with an Abbott model llA gamma counter (Abbott Diagnostics).
The amount of radioactivity remaining with the cell monolayer was determined by solubilizing the cell monolayer and attached platelets with 1.5 ml 2% Na2CO3 in 0.1 N NaOH. After solubilization this solution and a 1-ml wash were combined in a plastic centrifuge tube and 5'Cr radioactivity was determined. Percent adherence was calculated by dividing monolayer counts per minute by total counts per minute added to the dish, x 100.
Adherence of platelets to monolayers previously treated with thrombin. The cell monolayer was washed twice with 1.5 ml MHBSS. 1 ml IM (control) or 1 ml thrombin in IM was placed on the monolayer and the Petri dish was incubated without rocking for 5 min at 37°C. The preincubation solution was left on the monolayer and 0.5 ml 5'Cr-platelets in Tyrode's solution was immediately added to the 35 x 10-mm Petri dish, which then was rocked at 37°C for 30 min and handled as described above for adherence with thrombininduced preformed platelet aggregates.
Adherence of platelets to monolayers treated with aspirin. The monolayer was washed twice with 1.5 ml MHBSS. 1 ml IM (control) or 1 ml aspirin in IM was placed on the monolayer and the Petri dish was incubated with rocking for 30 min at 37°C. The aspirin or control solution was removed by aspiration and the dish was washed twice with 1.5 ml MHBSS. 1 ml IM (control) or 1 ml thrombin in IM was placed on the monolayer followed immediately by 0.5 ml untreated or aspirin-treated 5'Cr-platelets in Tyrode's solution. After rocking for 30 min at 37°C, the dish was handled as described above.
In additional studies, before thrombin and platelets were added, the dish was layered with culture medium (2 ml MM-199 with 20% FCS) and incubated in a 5% CO2 atmosphere at 37°C for various times. The medium was then removed and the monolayer was washed twice with MHBSS. Thrombin and platelets were then added and the dishes were handled as described above.
Electron microscopy studies. After removal of the nonadhering platelets and washing with MHBSS as described above, the monolayer was fixed with 1% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) and prepared for scanning electron microscopy according to a slight modification of the procedure described by Kelley et al. (21, 22) . The tissue was then incubated for 30 min with two changes of 100% ethanol, dried by the critical point method, coated with carbon and gold, and examined in a scanning electron microscope (Cambridge S4, Cambridge Instrument Co., Inc., Monsey, N. Y.).
Cells to be examined with transmission electron microscopy were fixed on the culture dish with 1% glutaraldehyde, postfixed in osmium tetroxide, dehydrated in graded alcohol solutions, and embedded in Epon-Araldite (Epon; Shell Chemical Co., Houston, Tex.; Araldite; Ciba-Geigy Corp., Ardsley, N. Y.). Sections were cut with a Reichert ultramicrotome (Reichert Stamping Co., Toledo, Ohio.) and diamond knife (E. I. Dupont de Nemours & Co., Inc., Wilmington, Del.) and were examined in a Philips EM 300 electron microscope (Philips Electronic Instruments, Inc., Mahwah, N. J.).
Statistical method. Student's t test (23) was employed to determine statistical significance.
RESULTS
Both untreated and aspirin-treated washed 5'Cr-platelets aggregated normally with 0.06 U/ml thrombin. Untreated washed platelets responded to thrombin (0.5 U/ ml) by forming MDA in a manner quantitatively similar (3.75+0.71 vs. 3.48+0.39 nmol MDA/109 platelets, P > 0.50) to platelets separated immediately from the initial platelet-rich plasma. In contrast, washed platelets incubated with 0.1-2.0 mM aspirin showed approximately a 95% reduction in thrombin-stimulated MDA relative to untreated washed platelets, with values similar to control MDA levels. The controls, which consisted of untreated or aspirin-treated platelets not incubated with thrombin, averaged 0.57+0.08 nmol MDA/109 platelets. This value compares well to the 0.39-0.81-nmol MDA/109 platelets range reported by Okuma et al. (24) .
In the adherence studies with preformed platelet aggregates (Table I) suspension of aggregates was incubated with empty dishes. When unaggregated platelets were added to fibroblast and smooth muscle cell monolayers after the monolayers were preincubated with 0.04-0.50 U thrombin (Table I) platelet adherence was similar to that observed with the 0.1-U thrombin-induced preformed aggregates. In contrast, endothelium did not exhibit this platelet adherence even at a thrombin concentration of 0.5 U/dish.
Adherence similar to that obtained with the thrombin preincubated monolayer system (Table I) was also observed if thrombin was added to endothelium, smooth muscle cells, or empty dishes simultaneously with the platelets (Fig. 1, open bars) . However, platelet adherence approaching that seen with 0.1 U thrombin-induced preformed platelet aggregates (Table I) could be obtained if the endothelium was first treated for 30 min with aspirin, washed, and then incubated with thrombin and platelets for an additional 30 min (Fig. 1, shaded bars) . In the absence of thrombin, the usual 1-2% base-line platelet adherence was found when the endothelium was first treated with 0.1-2.0 mM aspirin and then incubated with platelets. With 0.08 U thrombin (not shown in Fig. 1 Figs. 2 and 3 . Platelet aggregates remained attached to the endothelial monolayer, despite several washings, when preformed thrombin-induced aggregates were added to the monolayer or when unaggregated platelets were incubated with the endothelial monolayer after it had been exposed to thrombin. Transmission electron microscopy showed that aggregates of degranulated platelets adhered to the intact endothelium (Fig. 4) (10) who reported no interaction between normal, undamaged, bovine aortic endothelial monolayers and 125I-labeled bovine platelets. When platelets were preaggregated with thrombin (Table I) , adherence to the monolayers was observed but adherence to endothelium was significantly less (P < 0.01) than to fibroblast or smooth muscle cells, or to empty dishes. This difference, which is based on adherence of platelets to confluent cell monolayers with a surface area of 962 mm2, is further magnified if the cell count variation between endothelium (7-8 x 105 cells per 962 mm2), fibroblast (3-4 x 105), and smooth muscle cells (5-7 x 105) is taken into consideration. With thrombin-induced preformed platelet aggregate adherence to endothelium, the role ofthrombin is complex and may be effecting both platelets and endothelium. This is suggested by studies in which adherence to endothelium was reduced 75-90% when the thrombin-aggregated platelet suspension was exposed to hirudin. Hirudin, employed in a quantity sufficient to inhibit the amount of thrombin used to aggregate the platelets, was added to the thrombin aggregated platelet suspension before the aggregates were added to the endothelium. This is in marked contrast to the adherence of thrombin-induced preformed aggregates to the empty dish control in which previous hirudin neutralization of excess thrombin did not diminish the thrombin-induced adherence of preformed platelet aggregates.
The adherence of platelets to cell monolayers which had been pretreated with thrombin and then exposed to unaggregated platelets in the presence of the thrombin preincubation solution (Table I) These findings support the concept that the endothelium is relatively nonthrombogenic in comparison with other cell types. This characteristic may involve heparins on the endothelial cell surface (25, 26) , the reactivity of the plasma membrane, and the production of inhibitors. In earlier studies, Saba and Mason (27) and Saba et al. (28) , suggested that an inhibitor of platelet aggregation was produced in endothelium and could be released by the addition ofaggregating agents. Harker et al. (29) found a similar inhibitor of platelet function. Possibly involved in both cases is prostaglandin '2 (PGI2 or prostacyclin) (30) , a potent inhibitor of platelet aggregation probably produced in the vascular intima from prostaglandin endoperoxides (31) . Weksler et al. (32) have recently shown that endothelial cells cultured from the human umbilical cord vein do have the capacity to synthesize PGI2. In studies using a radioimmunoassay for 6-keto-prostaglandin Fin,,, the stable end product of PGI2, we have found that cultured endothelial cells but not our fibroblast or smooth muscle cells yield 6-keto-prostaglandin Fin in response to thrombin.2 Whether PGI2 is involved in the modification of thrombin-induced platelet adherence cannot be proven from the present work; additional studies are required to delineate this possibility.
A possible factor which could influence the difference in the adherence qualities between endothelium and the other cell types used in this study was that the fibroblasts and smooth muscle cells were passed FIGURE 2 Scanning electron micrograph of a thrombin-induced platelet aggregate which was adherent to the monolayer of the cultured endothelial cells. Magnification, X2,600.
cultures (5th-14th passage) aithough primary endothelial cultures were employed. This is unlikely to be a major factor because Essien et al. have found results comparable to ours using fresh tissues from the aorta of experimental animals. Thrombin caused adherence of platelets to the intact endothelium but caused even greater adherence to subendothelial tissues. 3 Pretreatment of the endothelium (Fig. 1 ) and platelets with aspirin gave results of particular interest. It is known that the endothelium can produce PGI2 (32), the inhibitor ofplatelet aggregation which is postulated to represent a key factor normally responsible for the nonthrombogenic properties of the vascular intima (30, 31) . Because aspirin blocks the cyclooxygenase activity in platelets which is responsible for the generation of endoperoxides involved in thromboxane formation (33) , it may also exert a similar effect on the endothelial cell and inhibit the production of PGI2.
In the present study our results suggest that aspirin 3 Personal communication concerning manuscript in preparation. Essien, E. M., J. P. Cazenave, S. Moore, and J. F. Mustard. Effect ofheparin and thrombin on platelet adherence to the surface of rabbit aorta. treatment of platelets had no effect on their adherence by thrombin. It should be noted that 0.1-2.0 mM aspirin-treated washed platelets in Tyrode's solution aggregated normally with thrombin but were inhibited by 95% in their ability to produce MDA. A 95% decrease in platelet MDA production by aspirin at a concentration of 0.01-0.10 mM has also been observed by Baenziger et al. (34) . MDA production is reported to correlate with platelet cyclooxygenase activity (33, 35) . However, a decrease in MDA production need not result only from decreased production of endoperoxides by the cyclooxygenase, but could also result from increased production of other endoperoxide products which do not break down into MDA (36) .
The effect of aspirin on adherence was upon the endothelium; the inhibitory properties of these cells could be decreased to the degree that platelet adherence approached that observed with smooth muscle cells and the empty dish control (Fig. 1) . Note that in the absence of thrombin only base-line adherence was observed with the aspirin-treated monolayers. In contrast, in the presence of thrombin, adherence above base line and nonaspirin-treated endothelium was obtained with endothelial cell monolayers pretreated with aspirin at 0.5-2.0 mM. At 0.5 U thrombin adherence increased from the 5-10% value associated with nonaspirin-treated endothelium and approached the 50% level by pretreating the monqlayer with 2.0 mM aspirin. Also note that 0.1 mM aspirin is sufficient to block 0.5 U thrombin-induced platelet MDA production but it does not interfere with the inhibitory effect of the endothelium. Pharmacologically, this 0.1-mM aspirin concentration to the 0.12 mM plasma concentration of unchanged aspirin observed 15 min after the ingestion of 650 mg aspirin (two 5-grain tablets) (37) or 30 min after the ingestion of 1,300 mg aspirin (38) . These plasma aspirin concentrations are 68% of that observed when the same dose is given intravenously (37) . Together, these data suggest that the endothelial adherence observations which involve 30-min incubations with 0.5-2.0 mM aspirin (Fig. 1 ) may have physiological significance only in situations involving prolonged or chronic use of high doses of aspirin. In contrast to its effect on platelet function (39) (40) (41) , the ability of aspirin to abolish endothelial cell inhibition to thrombin-induced platelet adherence is temporary. As shown in Table II , aspirin-treated endothelium almost completely recovers its capacity to inhibit adherence if placed in fresh growth medium for only 1 h before the incubation with thrombin and platelets. Villa and de Gaetano (42) have also noted a temporary, but longer-lasting effect of aspirin in in vivo studies with rat vascular tissue. Altogether, these data indicate that aspirin has an effect on the endothelium and can enhance platelet adherence if small amounts of thrombin are present. Such effects may help to explain the relatively slight impairment of clinical hemostasis caused by aspirin therapy despite profound alterations in platelet function measured with in vitro tests.
In determining the physiological significance of the platelet adherence observations reported in this study limitations ofthis and any in vitro model system should be considered. Although platelets were kept in a con-,'Th FIGURE 4 Transmission electron micrograph which shows sites of attachment of thrombintreated platelets to the endothelial cell. Magnification, x21,945. stant rocking motion, this cannot be assumed to represent the type of shear stress and flow exhibited in a pulsatile arterial system. Likewise, the limitation necessitated by use of cells from tissue culture is always a consideration. Even if primary endothelial cultures are representative of the in vivo situation, it is still not known whether human umbilical vein endothelial cells are representative of their adult counterparts. Even with these restrictions, our observations have implications for the mechanisms which operate in platelet interactions with cellular components of the blood vessel wall.
